Personalised Immunotherapy Arrives in the UAE: The First TILs Cancer Programme

The UAE has recently launched its first-ever tumour-infiltrating lymphocyte (TIL) therapy program, a monumental leap forward for cancer treatment in the Middle East. This innovation signifies a new era of personalised immunotherapy and an important treatment option for patients with advanced or treatment-resistant tumours.

Program Overview

The TIL therapy program offers an incredible opportunity for a patient to leverage his or her own immune system. The immune cells called lymphocytes that have already infiltrated the tumour (TILs) will be taken directly from the patient’s tumour tissue, then be cultured and expanded in rigorous good manufacturing practice GMP conditions, and activated, such that they are capable of enhanced tumour killing potential, and the cells are then placed back into the activated patient’s body. This is a unique highly personal cellular therapy that targets cancer cells while respecting healthy tissue. 

In the UAE, leading centres have successfully cultured TILs in breast and lung tumours in an observational study approved by the Department of Health – Abu Dhabi (DoH). The achievement of this program marks the first entry into this category of therapy in the UAE and opens up more opportunities for patients with cancer in the UAE.

Why is this a breakthrough

Traditional cancer modalities – chemotherapy, radiation – are often non-specific, and patients whose disease is not responsive (refractory) to these therapies have few therapeutic options. TIL offers a biologically tailored alternative: the therapy employs lymphocytes selected from the patient’s tumour, expanded, and returned to attack the disease. Its tantalising success in other malignancies (particularly melanoma) suggests broader applicability to solid tumours such as lung and breast. 

The local availability of the therapy is also notable. Rather than patients travelling abroad for access to advanced immunotherapy, the UAE will be able to facilitate treatment locally — potentially saving costs, travel burden and enhancing access to novel cancer therapy. The involvement of reputable medical institutions, such as the Cleveland Clinic Abu Dhabi and the SEHA, and local regulatory approval, demonstrates the ambition and the potential scope of this initiative.

National health-innovation context

The implementation of TIL is a programme launched as part of the UAE’s larger vision for advancing healthcare innovation and becoming a medical-research destination. It showcases the country’s commitment to adopting cutting-edge treatments while building the necessary infrastructure to advance the next phase of therapies. It is, of course, relevant that this is announced now, in advance of the UAE’s National Day celebrations, representing the importance of the programme in the development of the nation. 

Looking ahead—from programme to care standard

Although TIL therapy remains early-stage for many varieties of tumours, the UAE programme made important advances—sample collection, cell isolation and expansion, and reinfusion workflow are being established in the UAE. The next phase will include additional oversight with the clinical-trial process, developing and expanding treatment indication, enhancing regulatory oversight, and developing manufacturing and delivery. Eventually, the programme could expand to include engineered T-cells (TCR or CAR-T derivatives) to pinpoint tumours even more precisely.

Conclusion
The UAE is changing what cancer care will look like in the region with the delivery of personalised immunotherapy. A recent commencement of the first TIL-based therapy program has created a new avenue of hope for patients who have exhausted all standard treatment options. More broadly, this program reflects the progression of the new age of oncology, that the patient’s own immune system can be grown out to develop the treatment.